---
title: "浙江大学医学院第二附属医院发表在Cell 子刊上的研究，从临床问题出发，层层递进，逻辑清晰，做的太漂亮了！"
date: 2025-01-31T13:30:40Z
draft: ["false"]
tags: [
  "fetched",
  "小张聊科研"
]
categories: ["Acdemic"]
---
浙江大学医学院第二附属医院发表在Cell 子刊上的研究，从临床问题出发，层层递进，逻辑清晰，做的太漂亮了！ by 小张聊科研
------
<div><p><img data-imgfileid="508330932" data-ratio="0.41002570694087404" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/W1UqIxJECtzAetmvICaHU3Ju20X5FajQRqxQQD7WmfNvRK1ibHGlPxCEkdqNOoSicPENyobXfOLvhluQHayXTjibg/640?wx_fmt=other" data-type="other" data-w="778" src="https://mmbiz.qpic.cn/sz_mmbiz_png/W1UqIxJECtzAetmvICaHU3Ju20X5FajQRqxQQD7WmfNvRK1ibHGlPxCEkdqNOoSicPENyobXfOLvhluQHayXTjibg/640?wx_fmt=other"></p><p><span>今天我们介绍一项<span>浙江大学医学院第二附属医院发表在</span></span><span lang="EN-US">Cell </span><span>子刊上的研究，这项研究于</span><span lang="EN-US">2024</span><span>年</span><span lang="EN-US">12</span><span>月</span><span lang="EN-US">23</span><span>日发表于《</span><span lang="EN-US">CellReports Medicine</span><span>》期刊：</span><span lang="EN-US">MFGE8induces anti-PD-1 therapy resistance by promoting extracellular vesicle sortingof PD-L1</span><span>，研究主要通过机制探索和临床验证的研究策略，发现</span><strong><span lang="EN-US">MFGE8</span></strong><strong><span>通过促进</span></strong><strong><span lang="EN-US">PD-L1</span></strong><strong><span>在肿瘤细胞来源的细胞外囊泡（</span></strong><strong><span lang="EN-US">TEVs</span></strong><strong><span>）上的分选，诱导抗</span></strong><strong><span lang="EN-US">PD-1</span></strong><strong><span>疗法耐药</span></strong><span>，这项研究</span><span>从临床问题出发，层层递进，逻辑清晰，做的太漂亮了！</span><span lang="EN-US"><p></p></span></p><p><img data-imgfileid="508331076" data-ratio="0.2277456647398844" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/W1UqIxJECtzlG6sv7rm5OTtGms78iamCzf6ic4yjGcicM76nBA5k5IHhDn3rNManeP4S3e9CE8In325LibhTR9t59g/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="865" src="https://mmbiz.qpic.cn/sz_mmbiz_png/W1UqIxJECtzlG6sv7rm5OTtGms78iamCzf6ic4yjGcicM76nBA5k5IHhDn3rNManeP4S3e9CE8In325LibhTR9t59g/640?wx_fmt=png&amp;from=appmsg"><span lang="EN-US"></span><span lang="EN-US"><p></p></span></p><p><span>这篇文章的研究过程始于一个重要的临床问题：<strong><span>为什么许多肿瘤患者对免疫检查点抑制剂（如抗</span></strong></span><strong><span lang="EN-US">PD-1</span></strong><strong><span>疗法）表现出耐药性？</span></strong><span>尽管抗</span><span lang="EN-US">PD-1</span><span>疗法在多种晚期肿瘤中取得了突破，但大多数患者的临床响应率仍然很低，这促使研究团队深入探索耐药机制。</span><span lang="EN-US"><p></p></span></p><p><strong><span>一、从临床问题出发：耐药机制的探索</span></strong><strong><span lang="EN-US"><p></p></span></strong></p><p><span>研究团队首先注意到，<strong><span>肿瘤细胞来源的细胞外囊泡（</span></strong></span><strong><span lang="EN-US">TEVs</span></strong><strong><span>）在抑制抗肿瘤免疫中发挥重要作用。</span></strong><span lang="EN-US">TEVs</span><span>携带的</span><span lang="EN-US">PD-L1</span><span>能够与</span><span lang="EN-US">T</span><span>细胞上的</span><span lang="EN-US">PD-1</span><span>结合，从而抑制</span><span lang="EN-US">T</span><span>细胞的活性。因此，<strong><span>研究团队推测</span></strong></span><strong><span lang="EN-US">TEVs</span></strong><strong><span>上的</span></strong><strong><span lang="EN-US">PD-L1</span></strong><strong><span>可能是抗</span></strong><strong><span lang="EN-US">PD-1</span></strong><strong><span>疗法耐药的关键因素。</span></strong><strong><span>为了验证这一假设，研究团队设计了一系列实验，<span>通过敲除</span></span></strong><strong><span lang="EN-US">TEVs</span></strong><strong><span>分泌相关基因（如</span></strong><strong><span lang="EN-US">Rab27a</span></strong><strong><span>和</span></strong><strong><span lang="EN-US">Coro1a</span></strong><strong><span>），发现减少</span></strong><strong><span lang="EN-US">TEVs</span></strong><strong><span>的分泌能够显著增强抗</span></strong><strong><span lang="EN-US">PD-1</span></strong><strong><span>疗法的效果，而向肿瘤中补充</span></strong><strong><span lang="EN-US">TEVs</span></strong><strong><span>则会导致耐药性。</span></strong><span>这些结果表明，</span><span lang="EN-US">TEVs</span><span>上的</span><span lang="EN-US">PD-L1</span><span>确实是抗</span><span lang="EN-US">PD-1</span><span>疗法耐药的</span><span lang="EN-US">“</span><span>罪魁祸首</span><span lang="EN-US">”</span><span>。</span><span lang="EN-US"><p></p></span></p><p><strong><span>二、进一步探索：</span></strong><strong><span lang="EN-US">PD-L1</span></strong><strong><span>如何被分选到</span></strong><strong><span lang="EN-US">TEVs<p></p></span></strong></p><p><span>接下来，<strong><span>研究团队试图揭示</span></strong></span><strong><span lang="EN-US">PD-L1</span></strong><strong><span>是如何被分选到</span></strong><strong><span lang="EN-US">TEVs</span></strong><strong><span>中的。</span></strong><span>研究团队发现，随着肿瘤进展，</span><span lang="EN-US">TEVs</span><span>上的</span><span lang="EN-US">PD-L1</span><span>水平逐渐增加，<strong>这提示研究团队可能存在某种机制促进了</strong></span><strong><span lang="EN-US">PD-L1</span></strong><strong><span>的分选。</span></strong><span>通过分析</span><span lang="EN-US">PD-L1</span><span>的分选过程，研究团队发现</span><strong><span lang="EN-US">PD-L1</span></strong><strong><span>的泛素化修饰是关键步骤。泛素化修饰后的</span></strong><strong><span lang="EN-US">PD-L1</span></strong><strong><span>能够被</span></strong><strong><span lang="EN-US">ESCRT</span></strong><strong><span>复合体识别，并最终被分选到</span></strong><strong><span lang="EN-US">TEVs</span></strong><strong><span>中。</span></strong><span>通过一系列分子生物学实验，<strong><span>研究团队鉴定出</span></strong></span><strong><span lang="EN-US">UBE4A</span></strong><strong><span>是负责</span></strong><strong><span lang="EN-US">PD-L1</span></strong><strong><span>泛素化的</span></strong><strong><span lang="EN-US">E3</span></strong><strong><span>泛素连接酶。</span></strong><strong><span lang="EN-US">UBE4A</span></strong><strong><span>的过表达能够增加</span></strong><strong><span lang="EN-US">TEVs</span></strong><strong><span>上</span></strong><strong><span lang="EN-US">PD-L1</span></strong><strong><span>的水平，而</span></strong><strong><span lang="EN-US">UBE4A</span></strong><strong><span>的沉默则显著降低</span></strong><strong><span lang="EN-US">PD-L1</span></strong><strong><span>的水平。</span></strong><span>这些结果表明，</span><span lang="EN-US">UBE4A</span><span>介导的</span><span lang="EN-US">PD-L1</span><span>泛素化是</span><span lang="EN-US">PD-L1</span><span>分选到</span><span lang="EN-US">TEVs</span><span>的核心机制。</span><span lang="EN-US"><p></p></span></p><p><img data-imgfileid="508331077" data-ratio="0.35953757225433525" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/W1UqIxJECtzlG6sv7rm5OTtGms78iamCzHeib1Lt2rcXCGaIXFlyAk8nOPL7PgFF3jOicleZy5ianJIj4wibQFn5TWA/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="865" src="https://mmbiz.qpic.cn/sz_mmbiz_png/W1UqIxJECtzlG6sv7rm5OTtGms78iamCzHeib1Lt2rcXCGaIXFlyAk8nOPL7PgFF3jOicleZy5ianJIj4wibQFn5TWA/640?wx_fmt=png&amp;from=appmsg"><span lang="EN-US"></span><span lang="EN-US"><p></p></span></p><p><strong><span>三、深入挖掘：肿瘤细胞如何调控</span></strong><strong><span lang="EN-US">UBE4A<p></p></span></strong></p><p><strong><span>既然</span></strong><strong><span lang="EN-US">UBE4A</span></strong><strong><span>是关键因素，那么肿瘤细胞又是如何调控</span></strong><strong><span lang="EN-US">UBE4A</span></strong><strong><span>的表达呢？</span></strong><span>研究团队注意到，随着肿瘤进展，<strong><span>肿瘤细胞分泌的</span></strong></span><strong><span lang="EN-US">MFGE8</span></strong><strong><span>（乳脂球表皮生长因子</span></strong><strong><span lang="EN-US">8</span></strong><strong><span>）水平显著增加。</span></strong><strong><span lang="EN-US">MFGE8</span></strong><strong><span>能够激活整合素</span></strong><strong><span lang="EN-US">αvβ3/β5</span></strong><strong><span>信号通路，进而上调</span></strong><strong><span lang="EN-US">UBE4A</span></strong><strong><span>的表达。</span></strong><strong><span>为了验证这一点，<span>研究团队使用</span></span></strong><strong><span lang="EN-US">MFGE8</span></strong><strong><span>中和抗体（</span></strong><strong><span lang="EN-US">RM026</span></strong><strong><span>）阻断</span></strong><strong><span lang="EN-US">MFGE8</span></strong><strong><span>的功能，发现这不仅降低了</span></strong><strong><span lang="EN-US">UBE4A</span></strong><strong><span>的表达，还减少了</span></strong><strong><span lang="EN-US">TEVs</span></strong><strong><span>上</span></strong><strong><span lang="EN-US">PD-L1</span></strong><strong><span>的水平，并显著增强了抗</span></strong><strong><span lang="EN-US">PD-1</span></strong><strong><span>疗法的效果。</span></strong><span>这些结果表明，</span><span lang="EN-US">MFGE8</span><span>是通过上调</span><span lang="EN-US">UBE4A</span><span>来增加</span><span lang="EN-US">TEVs</span><span>上</span><span lang="EN-US">PD-L1</span><span>水平，从而导致抗</span><span lang="EN-US">PD-1</span><span>疗法耐药的。</span><span lang="EN-US"><p></p></span></p><p><strong><span>四、临床意义与展望</span></strong><strong><span lang="EN-US"><p></p></span></strong></p><p><span>基于这些发现，研究团队进一步分析了临床样本，<strong><span>发现患者血清中</span></strong></span><strong><span lang="EN-US">MFGE8</span></strong><strong><span>和</span></strong><strong><span lang="EN-US">TEVs</span></strong><strong><span>上</span></strong><strong><span lang="EN-US">PD-L1</span></strong><strong><span>的水平与抗</span></strong><strong><span lang="EN-US">PD-1</span></strong><strong><span>疗法的疗效密切相关。高水平的</span></strong><strong><span lang="EN-US">MFGE8</span></strong><strong><span>和</span></strong><strong><span lang="EN-US">PD-L1</span></strong><strong><span>预示着较差的预后。</span></strong><strong><span>因此，</span></strong><strong><span lang="EN-US">MFGE8</span></strong><strong><span>不仅是一个潜在的耐药机制，还可能作为预测抗</span></strong><strong><span lang="EN-US">PD-1</span></strong><strong><span>疗法响应的生物标志物。</span></strong><strong><span lang="EN-US"><p></p></span></strong></p><p><img data-imgfileid="508331078" data-ratio="0.6335260115606937" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/W1UqIxJECtzlG6sv7rm5OTtGms78iamCzoH2dYB3LcUVibDV8NSiaf2KtN8fv7Mwp5KBuYcOeAC39kgKEaW3wJesw/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="865" src="https://mmbiz.qpic.cn/sz_mmbiz_png/W1UqIxJECtzlG6sv7rm5OTtGms78iamCzoH2dYB3LcUVibDV8NSiaf2KtN8fv7Mwp5KBuYcOeAC39kgKEaW3wJesw/640?wx_fmt=png&amp;from=appmsg"><span lang="EN-US"></span><strong><span lang="EN-US"><p></p></span></strong></p><p><span>研究团队的研究为克服抗</span><span lang="EN-US">PD-1</span><span>疗法耐药提供了新的策略，即通过阻断</span><span lang="EN-US">MFGE8</span><span>来降低</span><span lang="EN-US">TEVs</span><span>上</span><span lang="EN-US">PD-L1</span><span>的水平，从而增强抗肿瘤免疫反应。通过这一系列从临床问题出发的实验探索，研究团队不仅揭示了抗</span><span lang="EN-US">PD-1</span><span>疗法耐药的新机制，还为未来的免疫治疗提供了新的靶点和思路。</span></p><p><span><img data-imgfileid="508331079" data-ratio="0.9953757225433526" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/W1UqIxJECtzlG6sv7rm5OTtGms78iamCzp70RGaEKoHibNfL4ZeCYlR4MYI3eXyOGtTPfQVfc4Olm5WXvFlYsfGg/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="865" src="https://mmbiz.qpic.cn/sz_mmbiz_png/W1UqIxJECtzlG6sv7rm5OTtGms78iamCzp70RGaEKoHibNfL4ZeCYlR4MYI3eXyOGtTPfQVfc4Olm5WXvFlYsfGg/640?wx_fmt=png&amp;from=appmsg"></span></p><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/feOsGA7blA-_aGGDPuScyQ",target="_blank" rel="noopener noreferrer">原文链接</a>
